22833-69-8

Basic information

• Product Name: METHYL 2-HYDROXY-6-METHOXYBENZOATE
• Synonyms: Benzoic acid, 2-hydroxy-6-methoxy-, methyl ester
• CAS NO: 22833-69-8
• Molecular Formula: C₉H₁₀O₄
• Molecular Weight: 182.17
• Product Categories: Aromatic Esters
• Mol File: 22833-69-8.mol
• Article Data: 19

Chemical Properties

• Melting Point: 50-52 °C
• Boiling Point: 134-138 °C(Press: 9 Torr)
• Appearance: /
• Density: 1.216±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.38±0.10(Predicted)
• CAS DataBase Reference: METHYL 2-HYDROXY-6-METHOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-HYDROXY-6-METHOXYBENZOATE(22833-69-8)
• EPA Substance Registry System: METHYL 2-HYDROXY-6-METHOXYBENZOATE(22833-69-8)

Safety Data

• Hazardous Substances Data: 22833-69-8(Hazardous Substances Data)

Usage

Description

METHYL 2-HYDROXY-6-METHOXYBENZOATE, also known as methyl homoprotocatechuate, is an organic compound with the chemical formula C10H12O4. It is a derivative of benzoic acid and is characterized by its antimicrobial properties and ability to inhibit the growth of various microorganisms.
Used in Pharmaceutical Industry:
METHYL 2-HYDROXY-6-METHOXYBENZOATE is used as a preservative for its antimicrobial properties, helping to maintain the shelf life and safety of pharmaceutical products.
Used in Cosmetic Industry:
METHYL 2-HYDROXY-6-METHOXYBENZOATE is used as a preservative in cosmetics for its ability to inhibit the growth of microorganisms, ensuring the product's stability and safety for consumers.
Used in Fragrance Industry:
METHYL 2-HYDROXY-6-METHOXYBENZOATE is used as a fragrance ingredient due to its aromatic properties, contributing to the scent of various products.
Used in Organic Synthesis:
METHYL 2-HYDROXY-6-METHOXYBENZOATE is used as a building block in the synthesis of other organic compounds, making it a valuable component in chemical research and development.
Used in Medicinal Chemistry:
METHYL 2-HYDROXY-6-METHOXYBENZOATE has potential applications in medicinal chemistry, where its unique properties may be harnessed for the development of new pharmaceuticals and treatments.

Upstream product

• 2150-45-0 methyl 2,6-dihydroxybenzoate 
• 67-56-1 methanol 
• 145645-17-6 methyl 2-methoxy-6-(methoxymethoxy)benzoate 
• 3147-64-6 2-hydroxy-6-methoxybenzoic acid 
• 74-88-4 methyl iodide 
• 2065-27-2 methyl 2,6-dimethoxybenzoate 
• 303-07-1 2,6-Dihydroxybenzoic acid 
• 30778-86-0 1-methoxy-3-tetrahydropyran-2-yloxybenzene 
• 154045-69-9 1,2-dimethoxy-3-(methoxymethoxy)benzene 
• 186581-53-3 diazomethane 
• 606-45-1 2-methoxybenzoic acid methyl ester 
• 1146214-77-8 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester 

Downstream Products

• 145645-18-7 methyl 2-methoxy-6-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 146984-70-5 methyl 3-chloro-6-hydroxy-2-methoxybenzoate 
• 146984-69-2 methyl 3-chloro-2-hydroxy-6-methoxybenzoate 
• 80900-55-6 methyl 2-(t-butyldimethylsiloxy)-6-methoxybenzoate 
• 475630-76-3 methyl 6-methoxy-2-(perfluoro-1-butanesulfonyloxy)benzoate 
• 6563-60-6 methoxy-9H-xanthen-9-one 
• 921207-63-8 methyl 2-methoxy-6-vinylbenzoate 
• 921207-73-0 methyl 2-{(1E,4R)-4-benzyloxy-5-[(2S,4R,6S)-6-(3-benzyloxy-propyl)-2-phenyl-1,3-dioxan-4-yl]pent-1-enyl}-6-methoxy-benzoate 
• 570397-58-9 (3S,5R,7R)-7-(benzyloxy)-3-[3-(benzyloxy)propyl]-5-hydroxy-14-methoxy-3,4,5,6,7,8-hexahydro-1H-2-benzoxacyclododecin-1-one 
• 147666-84-0 3-(3,4-dimethoxyphenyl)-8-methoxyisochromen-1-one 
• 475630-78-5 methyl 2-(3,4-dimethoxyphenyl)ethynyl-6-methoxybenzoate 
• 475630-84-3 4-iodo-3-(3,4-dimethoxyphenyl)-8-methoxyisocoumarin 
• 404936-52-3 (3S,5R)-3-[3-(benzyloxy)propyl]-5-hydroxy-14-methoxy-3,4,5,6,7,8-hexahydro-1H-2-benzoxacyclododecin-1-one 
• 404936-50-1 methyl 2-[(1E,6R,8S)-11-(benzyloxy)-6,8-dihydroxy-1-undecenyl]-6-methoxybenzoate 

Relevant articles and documents

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES

The present invention discloses compounds according to Formula (I), wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

N,B-bidentate boryl ligand-supported iridium catalyst for efficient functional-group-directed C-H borylation

Convenient silylborane precursors for introducing N,B-bidentate boryl ligands onto transition metals were designed, prepared, and employed in ready formation of irdium(IIl) complexes via Si-B oxidative addition. A practical, efficient catalytic ortho-borylation reaction of arenes with a broad range of directing groups was developed using an in situ generated catalyst from the silylborane preligand 3c and [IrCl(COD)]2.

2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-pyridyloxy-3-ester-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prev